• New Guide Provides Information on Benefits of Multidisciplinary Care for ALS Treatment
  • Anti-epilectic Compound Shows Neuroprotective Effects in ALS Worm Model, Study Reports
  • Stumbling Upon an ALS-free Zone
  • Phase 1/2 Trial Testing IONIS-SOD1Rx for ALS Launched After Positive Findings in Animal Models
  • When ALS Becomes a Hard Act to Swallow
  • CannTrust Partnering with Australian Hospital for Trial Testing Cannabidiol Capsules for ALS
  • Boosting Protein with Role in Getting Nutrients to Cells Prevented Muscle Wasting in ALS Mice, Study Finds
  • Right to Try vs. Right to Say No: An Open Letter to Lawmakers
  • Ibudilast Added to Rilutek Improves Function in ALS Patients, Phase 2 Trial Shows
  • Phase 3 Trial of Oral Levosimendan as Respiratory Treatment for ALS Recruiting in US, Europe and Australia
  • 2 miRNAs Controlling Genes Involved in ALS, and Possible Way of Regulating Them, Identified in Study
  • FDA Approves Xeomin for Excessive Drooling, Common in ALS Patients